Fresenius Group Overview

Financial Results

To archive

FY/20 Results

Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact

  • Preliminary guidance for 2021 confirmed

  • Strategic roadmap for accelerated growth through 2023 and beyond

  • Group-wide initiatives to improve efficiency and profitability in preparation

  • Medium-term growth targets confirmed

  • 28th consecutive dividend increase proposed

Sales growth analysis
png
Sales by business segment

 

€ in millions

 2020

 2019

Change

Organic sales growth Currency translation effects Acquisitions Divestitures % of total sales1

Fresenius Medical Care

17,859 17,477 2% 3% -3% 3% -1% 49%

Fresenius Kabi

6,976 6,919 1% 4% -3% 0% 0% 19%

Fresenius Helios

9,818 9,234 6% 4% -1% 3% 0% 27%
Fresenius Vamed 2,068 2,206 -6% -8% 0% 2% 0% 5%

Total

36,277 35,409 2% 3% -3% 2% 0% 100 %

1 The following description of sales relates to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

Selected Key Figures FY/2020

Sales

€ 36277 m

+5% 1

FY/19: €35,409 m

EBIT 2

€ 4612 m

0% 1

FY/19: €4,688 m

Net Income 2, 3

€ 1796 m

-3% 1

FY/19: €1,879 m

Earnings per Share 2, 3

€ 3.22

-3% 1

FY/19: €3.37

 

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

Archive